Glycine: Evidence, Dosage & Safety Guide

a person's shadow is cast on the wall of a bedroom
```html

Glycine: Evidence-Based Benefits, Dosage and Safety (UK Guide)

Glycine is a simple amino acid your body uses to build protein, support connective tissue, and modulate neurotransmission. At 2000mg per serving, it sits within the dose range studied in human trials. The evidence base is modest but growing; I'll walk you through what the data actually shows, what remains uncertain, and whether it belongs in your routine.

What is Glycine?

Glycine is the smallest amino acid, synthesised naturally from serine and obtained from collagen-rich foods. It is conditionally essential—your body produces some, but demand may exceed supply during stress, intense training, or ageing. In crystalline form, it crosses the blood-brain barrier and acts as an inhibitory neurotransmitter whilst serving as a precursor for creatine, glutathione, and haem synthesis.

Glycine is the smallest amino acid — a building block of protein with a single hydrogen atom as its side chain. Your body synthesises it naturally from serine and other precursors, and you also obtain it from dietary protein, especially collagen-rich foods like bone broth and skin. Unlike the nine essential amino acids you must obtain from food, glycine is conditionally essential: your body can make some, but demand may exceed supply during periods of stress, intense training, or ageing.

In KōJō Daily Formula, glycine is supplied as crystalline powder — the most bioavailable and cost-effective form. Once ingested, it enters the bloodstream and crosses the blood-brain barrier, where it acts as a co-agonist at NMDA receptors and as a standalone inhibitory neurotransmitter in the spinal cord and brainstem. It also serves as a precursor for creatine, glutathione, and haem synthesis.

Glycine sits at a metabolic crossroads. It participates in collagen formation, immune regulation, and the synthesis of nucleotides for DNA replication. This broad role is why research has explored its use across sleep, joint health, mood, and gut barrier function — though the human evidence for most claims remains preliminary.

Clinical Evidence

Human RCT data is modest and heterogeneous. No large, multi-centre trial demonstrates glycine as a first-line treatment for any condition. Sleep studies show the most consistent evidence: glycine may lower core body temperature and promote sleep transitions at 3–5g doses. Evidence for joint health, mood, and metabolic disease remains suggestive rather than conclusive, with most positive findings from animal models or mechanistic studies.

The human RCT data for glycine is modest in volume and heterogeneous in outcome. I want to be direct: there is no large, well-powered, multi-centre trial demonstrating that glycine at any dose is a first-line treatment for any condition. Small, mostly positive studies exist in specific populations. That matters, because it means the evidence is suggestive but not conclusive.

The most consistent evidence centres on sleep. Hall (1999) provides foundational biochemistry on glycine's role as an inhibitory neurotransmitter. Several small RCTs have examined glycine supplementation in people with sleep complaints. Research suggests glycine may lower core body temperature and promote sleep-stage transitions. The typical dose in these trials is 3–5g, slightly higher than KōJō's 2000mg per serving. Whether 2000mg alone is sufficient for sleep effects remains an open question; you might need multiple servings or to stack it with other sleep-supporting ingredients.

Glycine's role in collagen and connective tissue has attracted interest in joint and skin health. Matar et al. (2025) reviewed bone broth — a rich source of glycine — and noted that its amino acid profile, including glycine, may support gut barrier integrity. The mechanism is plausible: glycine is a key component of collagen, and collagen is a structural foundation of the intestinal wall. However, direct human RCT evidence that oral glycine supplementation rebuilds gut barrier function is limited. Most positive findings come from animal models or mechanistic studies.

Glycine has also been examined in the context of mood and neuroinflammation. Henter et al. (2022) surveyed glutamatergic modulators for mood disorders and noted glycine as a potential co-modulator due to its NMDA receptor activity. The evidence is largely preclinical; human trials are scarce and sample sizes are small. In clinical populations with depression or anxiety, glycine has not yet demonstrated efficacy comparable to established treatments.

Glycine depletion has been documented in metabolic disease. Ghrayeb et al. (2024) found that glycine depletion occurs in metabolic-associated fatty liver disease (MASLD), suggesting glycine may play a protective role in hepatic metabolism. This is mechanistically interesting but does not yet translate to a clinical recommendation for supplementation in MASLD. Research suggests that restoring glycine levels through supplementation may influence liver disease, but direct human evidence remains absent.

Across the literature, glycine supplementation is generally well-tolerated. Adverse events are rare, and no serious toxicity has been reported at doses up to 10g daily in human studies. The lack of negative data is reassuring but also reflects the small sample sizes and short durations of most trials. Long-term safety at high doses (above 5g daily) has not been rigorously studied in large populations.

Dosage: What Research Supports

Clinical trials typically use 1000–5000mg daily, split across servings. Sleep studies favour the higher end (3–5g), whilst mechanistic studies use 2000–3000mg. The EFSA has not set a formal recommended daily allowance for glycine supplementation. KōJō Daily Formula provides 2000mg per serving, aligning with the lower-to-mid range and sitting comfortably within documented safety profiles.

Clinical studies of glycine have typically used doses ranging from 1000mg to 5000mg per day, often split into multiple servings. Sleep studies tend toward the higher end (3–5g), whilst mechanistic and gut health studies have used 2000–3000mg. The European Food Safety Authority (EFSA) has not set a formal recommended daily allowance for glycine supplementation, as it is not classified as an essential nutrient in the traditional sense. The UK's NHS does not list glycine as a standard nutritional requirement, though it acknowledges glycine's role in normal protein metabolism.

KōJō Daily Formula provides 2000mg of crystalline glycine per serving. This dose aligns with the lower-to-mid range of clinical trials and sits comfortably within the safety profile documented in the literature. If your goal is sleep support or connective tissue health, 2000mg once daily may be a reasonable starting point; some people add a second serving in the evening. If you are exploring glycine for a specific condition — joint recovery, mood support, or metabolic health — discuss dosing strategy with a healthcare professional, as the evidence for optimal dosing in these contexts is still emerging.

How KōJō Uses Glycine

Crystalline glycine powder offers superior bioavailability and cost-effectiveness. It is rapidly absorbed, crosses the blood-brain barrier efficiently, and synergises with other formula ingredients—particularly vitamin C for collagen cross-linking and B vitamins for neurotransmitter metabolism. The 2000mg dose is intentionally moderate: practical, stackable, mechanistically supported, and within the safe and studied range.

I chose crystalline glycine powder for three reasons: bioavailability, cost-effectiveness, and interaction with the broader formula. Crystalline glycine is rapidly absorbed and crosses the blood-brain barrier efficiently. It pairs well with other amino acids and micronutrients in the formula that support neurotransmission, collagen synthesis, and antioxidant defence — for instance, vitamin C, which is a cofactor for collagen cross-linking, and B vitamins, which support neurotransmitter metabolism.

The 2000mg dose per serving is intentionally moderate. Rather than chase the highest dose in the literature, I've sized it to be practical — easy to consume, stackable if needed, and supported by mechanistic evidence even if human RCT data is thin. This reflects my philosophy: ingredients included in KōJō Daily Formula should have a plausible mechanism, some human data (even if preliminary), and a dose that sits within the safe and studied range. Glycine meets all three criteria.

Safety and Considerations

Glycine is remarkably safe; no serious adverse events occur at doses up to 10g daily. Mild gastrointestinal upset is rare. Glycine does not accumulate to toxic levels. Pregnant or breastfeeding individuals, those taking neurotransmission-affecting medications (benzodiazepines, antidepressants, antipsychotics), and those with kidney or liver disease should consult a healthcare provider before supplementing.

Glycine is remarkably safe. No serious adverse events have been reported in the human literature at doses up to 10g daily. Common side effects are minimal — occasional mild gastrointestinal upset or headache in isolated cases, but these are rare and typically resolve quickly. Unlike some amino acids, glycine does not accumulate to toxic levels in the body; excess is readily excreted or metabolised.

That said, a few populations should exercise caution. If you are pregnant or breastfeeding, consult your healthcare provider before starting glycine supplementation; the evidence base in these groups is absent. If you are taking medications that affect neurotransmission — particularly benzodiazepines, antidepressants, or antipsychotics — inform your doctor, as glycine's NMDA modulation is theoretically relevant (though clinically significant interactions are undocumented). If you have an underlying condition affecting kidney or liver function, discuss glycine supplementation with your clinician, as these organs are involved in amino acid metabolism. KōJō Daily Formula provides 2000mg of crystalline glycine per serving — stay within the single-serving guidance unless your healthcare provider advises otherwise.

Limitations of Current Evidence

Most human trials are small (20–50 participants), short-term (weeks to months), and conducted in narrow populations. Few head-to-head comparisons exist. Long-term safety beyond 5g daily remains understudied. For sleep, joint health, mood, and metabolic disease, evidence is suggestive rather than conclusive. Glycine is not a replacement for established medical treatment, and individual responses vary widely.

The glycine evidence base has real gaps. Most human trials are small (typically 20–50 participants), short-term (weeks to a few months), and conducted in narrow populations. There are few head-to-head comparisons with other interventions. Long-term supplementation safety beyond 5g daily remains understudied. For sleep, joint health, mood, and metabolic disease, the data is suggestive rather than conclusive. If you are considering glycine for a specific health goal, manage expectations: it is not a replacement for established medical treatment, and individual responses vary widely.

Frequently Asked Questions

What does glycine do? Glycine supports protein synthesis and collagen formation; it acts as an inhibitory neurotransmitter and precursor for creatine and glutathione. Research suggests benefits for sleep, joint health, and gut barrier function, though human evidence remains preliminary. How much per day? Clinical trials use 1000–5000mg; sleep studies favour 3–5g. KōJō provides 2000mg per serving. Optimal dosing should be discussed with a healthcare professional. Is it safe? Yes—well-tolerated at up to 10g daily with no serious adverse events reported.

What does glycine do?

Glycine is an amino acid that contributes to normal protein synthesis and collagen formation. Hall (1999) describes its roles as an inhibitory neurotransmitter and precursor for creatine and glutathione. Research suggests it may support sleep, joint health, and gut barrier function, though human evidence is preliminary.

How much glycine should I take per day?

Clinical trials have used 1000–5000mg daily, depending on the outcome studied. Sleep studies typically use 3–5g, whilst general health studies use 2–3g. KōJō Daily Formula provides 2000mg per serving. Optimal dosing for your individual goals should be discussed with a healthcare professional, as evidence varies by application.

Is glycine safe?

Yes. Glycine is well-tolerated at doses up to 10g daily in human studies, with no serious adverse events reported. Mild gastrointestinal upset is rare. If you are pregnant, breastfeeding, taking medications affecting neurotransmission, or have kidney or liver disease, consult your healthcare provider before supplementing.

How long does glycine take to work?

This depends on the outcome. For sleep, some people report effects within days to weeks of consistent use. For connective tissue and collagen-related effects, changes typically emerge over weeks to months, as collagen remodelling is a slow process. Mechanistic effects on neurotransmission may be immediate, but functional benefits require sustained use.

Can I take glycine every day?

Yes. Glycine is safe for daily use at the doses provided in supplements. Your body regulates glycine levels through synthesis and excretion, so there is no known risk of accumulation. For best results, consistency matters more than occasional high doses; daily intake allows steady availability for collagen synthesis and neurotransmitter support.

What's the best form of glycine?

Crystalline powder — the form used in KōJō Daily Formula — is the most bioavailable and cost-effective. It is rapidly absorbed and crosses the blood-brain barrier efficiently. Glycine chelated to other minerals (e.g. glycine citrate) may offer additional benefits, but standard crystalline glycine is well-researched and effective.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.

References (7 studies)
  1. Hall (1999)
  2. Matar et al. (2025)
  3. Henter et al. (2022)
  4. Ghrayeb et al. (2024)
  5. Cicero et al. (2020)
  6. Cullinane et al. (2024)
  7. Xu et al. (2022)
```